Alnylam Expands Asian Presence With RNAi License To Japan's GeneDesign
This article was originally published in PharmAsia News
Executive Summary
Alnylam Pharmaceuticals has granted Osaka, Japan-based GeneDesign a nonexclusive license to provide small interfering RNA research products and services using Alnylam's Kreutzer-Limmer patent estate, the companies announced Oct. 3
You may also be interested in...
Asia Partnerships Critical To Big Pharma’s Drying Pipelines, Merck Exec Tells Bio Korea (Part 1 of 2)
OSONG, Korea - As big pharma continues snatching up biotechs in its quest to fill drying pipelines, very few biotechs will be left standing in 2013, Merck exec Greg Wiederrecht told Bio Korea attendees Oct. 8.
Asia Partnerships Critical To Big Pharma’s Drying Pipelines, Merck Exec Tells Bio Korea (Part 1 of 2)
OSONG, Korea - As big pharma continues snatching up biotechs in its quest to fill drying pipelines, very few biotechs will be left standing in 2013, Merck exec Greg Wiederrecht told Bio Korea attendees Oct. 8.
Alnylam Makes Entry Into Chinese RNAi Market
Chinese small interfering siRNA supplier Shangahi GenePharma has acquired a nonexclusive worldwide license to Alnylam Pharmaceuticals' Kreutzer-Limmer patent group, which is the first business transaction in China made by the Cambridge, Mass.-based RNAi firm